Corpus overview


MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

ProteinS (1)

ProteinE (1)

ORF7b (1)

ORF8 (1)

ORF10 (1)


SARS-CoV-2 Proteins
    displaying 1 - 3 records in total 3
    records per page

    The BNT162b2 mRNA vaccine against SARS-CoV-2 reprograms both adaptive and innate immune responses

    Authors: F. Konstantin Fohse; Busranur Geckin; Gijs J. Overheul; Josephine van de Maat; Gizem Kilic; Ozlem Bulut; Helga Dijkstra; Heidi Lemmers; S. Andrei Sarlea; Maartje Reijnders; Jacobien Hoogerwerf; Jaap ten Oever; Elles Simonetti; Frank L. van de Veerdonk; Leo A. B. Joosten; Bart L. Haagmans; Reinout van Crevel; Yang Li; Ronald P. van Rij; Corine GeurtsvanKessel; Marien I. de Jonge; Jorge Dominguez-Andres; Mihai G. Netea

    doi:10.1101/2021.05.03.21256520 Date: 2021-05-06 Source: medRxiv

    The mRNA-based BNT162b2 vaccine from Pfizer/BioNTech was the first registered COVID-19 MESHD vaccine and has been shown to be up to 95% effective in preventing SARS-CoV-2 infections MESHD SARS-CoV-2 infections MESHD. Little is known about the broad effects of the new class of mRNA vaccines, especially whether they have combined effects on innate and adaptive immune responses. Here we confirmed that BNT162b2 vaccination of healthy individuals induced effective humoral and cellular immunity against several SARS-CoV-2 variants. Interestingly, however, the BNT162b2 vaccine also modulated the production of inflammatory cytokines by innate immune cells upon stimulation with both specific (SARS-CoV-2) and non-specific (viral, fungal and bacterial) stimuli. The response of innate immune cells to TLR4 HGNC and TLR7 HGNC/8 ligands was lower after BNT162b2 vaccination, while fungi-induced cytokine responses were stronger. In conclusion, the mRNA BNT162b2 vaccine induces complex functional reprogramming of innate immune responses, which should be considered in the development and use of this new class of vaccines.

    Designing a new multi epitope-based vaccine against COVID-19 MESHD disease: an immunoinformatic study based on reverse vaccinology approach

    Authors: Afshin Samimi Nemati; Majid Tafrihi; Fatemeh Sheikhi; Abolfazl Rostamian Tabari; Amirhossein Haditabar

    doi:10.21203/ Date: 2021-02-04 Source: ResearchSquare

    Severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) has currently caused a significant pandemic among worldwide populations. The transmission speed and the high rate of mortality caused by the disease necessitate studies for the rapid designing and effective vaccine production. The purpose of this study is to predict and design a novel multi-epitope vaccine against the SARS-CoV-2 virus using bioinformatics approaches. Coronavirus envelope proteins PROTEIN, ORF7b PROTEIN, ORF8 PROTEIN, ORF10 PROTEIN, and NSP9 PROTEIN were selected as targets for epitope mapping using IEDB and BepiPred 2.0 Servers. Also, molecular docking studies were performed to determine the candidate vaccine's affinity to TLR3 HGNC, TLR4 HGNC, MHC I, and MHC II molecules. Thirteen epitopes were selected to construct the multi-epitope vaccine. We found that the constructed peptide has valuable antigenicity, stability, and appropriate half-life. The Ramachandran plot approved the quality of the predicted model after the refinement process. Molecular docking investigations revealed that antibody-mode in the Cluspro 2.0 server showed the lowest binding energy for MHCI, MHCII, TLR3 HGNC, and TLR4 HGNC. This study confirmed that the designed vaccine has a good antigenicity and stability and could be a proper vaccine candidate against the COVID-19 MESHD infectious disease MESHD though, in vitro and in vivo experiments are necessary to complete and confirm our results.

    A vaccine built from potential immunogenic pieces derived from the SARS-CoV-2 spike PROTEIN glycoprotein

    Authors: Jose Gregorio Marchan; Camille R. Simoneau; Jessie Kulsuptrakul; Mehdi Bouhaddou; Katherine Travisano; Jennifer M. Hayashi; Jared Carlson-Stevermer; Jennifer Oki; Kevin Holden; Nevan J. Krogan; Melanie Ott; Andreas S Puschnik; I. A. Rodenhuis-Zybert; J. M. Smit; Qiang Wang; Xueqin Huang; Qingsong Xu; Mei Luo; Dongxia Luo; Chenyan Zhao; Jian-Bao Han; Yong-Tang Zheng; Peng Liang

    doi:10.1101/2020.09.24.312355 Date: 2020-09-24 Source: bioRxiv

    Coronavirus Disease 2019 MESHD ( COVID-19 MESHD) represents a new global threat demanding a multidisciplinary effort to fight its etiological agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In this regard, immunoinformatics may aid to predict prominent immunogenic regions from critical SARS-CoV-2 structural proteins, such as the spike (S PROTEIN) glycoprotein, for their use in prophylactic or therapeutic interventions against this rapidly emerging coronavirus. Accordingly, in this study, an integrated immunoinformatics approach was applied to identify cytotoxic T cell (CTC), T helper cell (THC), and Linear B cell (BC) epitopes from the S glycoprotein PROTEIN in an attempt to design a high-quality multi-epitope vaccine. The best CTC, THC, and BC epitopes showed high viral antigenicity, lack of allergenic MESHD or toxic residues, and suitable HLA-viral peptide interactions. Remarkably, SARS-CoV-2 receptor-binding domain (RBD) and its receptor-binding motif (RBM) harbour several potential epitopes. The structure prediction, refinement, and validation data indicate that the multi-epitope vaccine has an appropriate conformation and stability. Three conformational epitopes and an efficient binding between Toll-like receptor 4 HGNC ( TLR4 HGNC) and the vaccine model were observed. Importantly, the population coverage analysis showed that the multi-epitope vaccine could be used globally. Notably, computer-based simulations suggest that the vaccine model has a robust potential to evoke and maximize both immune effector responses and immunological memory to SARS-CoV-2 MESHD. Further research is needed to accomplish with the mandatory international guidelines for human vaccine formulations.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.